Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Big data and Life Sciences Guy Coates Wellcome Trust Sanger Institute [email protected] The Sanger Institute Funded by Wellcome Trust. • 2nd largest research charity in the world. • ~700 employees. • Based in Hinxton Genome Campus, Cambridge, UK. Large scale genomic research. • Sequenced 1/3 of the human genome. • (largest single contributor). Large scale sequencing with an impact on human and animal health. Data is freely available. • Websites, ftp, direct database access, programmatic APIs. • Some restrictions for potentially identifiable data. My team: • Scientific computing systems architects. DNA Sequencing TCTTTATTTTAGCTGGACCAGACCAATTTTGAGGAAAGGATACAGACAGCGCCTG AAGGTATGTTCATGTACATTGTTTAGTTGAAGAGAGAAATTCATATTATTAATTA TGGTGGCTAATGCCTGTAATCCCAACTATTTGGGAGGCCAAGATGAGAGGATTGC ATAAAAAAGTTAGCTGGGAATGGTAGTGCATGCTTGTATTCCCAGCTACTCAGGAGGCTG TGCACTCCAGCTTGGGTGACACAG CAACCCTCTCTCTCTAAAAAAAAAAAAAAAAAGG AAATAATCAGTTTCCTAAGATTTTTTTCCTGAAAAATACACATTTGGTTTCA ATGAAGTAAATCG ATTTGCTTTCAAAACCTTTATATTTGAATACAAATGTACTCC 250 Million * 75-108 Base fragments Human Genome (3GBases) ~1 TByte / day / machine Economic Trends: Cost of sequencing halves every 12 months. • Wrong side of Moore's Law. The Human genome project: • 13 years. • 23 labs. • $500 Million. A Human genome today: • 3 days. • 1 machine. • $8,000. Trend will continue: • $1000 genome is probable within 2 years. • Informatics not included. The scary graph Peak Yearly capillary sequencing: 30 Gbase Current weekly sequencing: 7-10 Tbases Data doubling Time: 4-6 months. Gen III Sequencers this year? Sequencing data flow. Sequencer Processing/ QC Comparative analysis Archive Internet Structured data (databases) Unstructured data (Flat files) Pbytes! Raw data (10 TB) Sequence (500GB) Alignments (200GB) Variation data (1GB) Feature (3MB) A Sequencing Centre Today CPU • Generic x86_64 cluster. • (16,000 cores) Storage • ~1 TB per day per sequencer. • • (15 PB disk) (Lustre + NFS) Metadata driven data management • Only keep our important files. • Catalogue them, so we can find them! • Keep the number of copies we want, and no more. • (iRODS, in house LIMs). A solved problem; we know how to do this. This is not big data This is not big data either... Proper Big Data We want to compute across all the data. • Sequencing data (of course). • Patient records, treatment and outcomes. Why? • Cancer: tie in genetics, patient outcomes and treatments. • Pharma: high failure rate due to genetic factors in drug response. • Infectious disease epidemiology. • Rare genetic diseases. Many genetic effects are small • Million member cohorts to get good signal:noise. Translation: Genomics of drug sensitivity in Cancer BRAF Inhibitors in maligant melanoma BRAF inhibitor 15 weeks of treatment Pre-treatment molecular diagnostic BRAF mutation positive ✔ 70% response rate vs 10% for standard chemotherapy Slide from Mathew Garnet (CGP) Current Data Archives EBI ERA / NCBI SRA store results of all sequencing experiments. • Public data availability: A good thing (tm) • 1.6 Pbases Problems • Archives are “dark”. • You can put data in, but you can't • do anything with it. In order to analyse the data, you need to download it all. • 100s of Tbytes Situation replicated at local Institute level too. • eg How does CRI get hold of their data currently held at Sanger? The Vision Global Alliance for sharing genomic and clinical data • 70 research institutes & hospitals (including Sanger, Broad, EBI, BGI, Cancer Research UK) Million cancer genome warehouse • (UC Berkeley) To the Cloud! Institute A Analysis pipeline Data Analysis pipeline Analysis pipeline Data Analysis pipeline Data Data Institute B Analysis pipeline Data Data How do we get there? Code & Algorithms Bioinformatics code: • Integer not FP heavy. • Single threaded. • Large memory footprints. • Interpreted languages. Not a good fit for future computing architectures. Expensive to run on public clouds. • Memory footprint leads to unused cores. Out of scope for a data talk, but still an important point. Architectural differences dynamic nodes cpu cpu Static nodes cpu cpu cpu cpu cpu VS Fast Network Global File system cpu Slow Network Object Store Whose Cloud? A VM is just a VM, right? • Clouds are supposed to be • programmable. Nobody wants to re-write a pipeline when they move clouds. Storage: • Posix: • (lustre/GPFS/EMC)? Object: • Low level: AWS S3, Openstack SWIFT, Ceph/rados • High level: Data management layer (eg iRODS)? • Cloud Interoperability? • Do we need is more standards?! Pragmatic approach: • First person to make one that actually works, wins. Moving data Data still has to get from our instruments to the Cloud. Good news: • Lots of products out there for wide area data movement. Bad news: • We are currently using all of them(!) Network bandwidth still a problem. • Research institutes have fast data networks. • What about your GP's surgery? UDT / UDR genetorrent rsync / ssh Identity Access Unlikely that data archives are going to allow anonymous access. • Who are you? Federated identify providers. • Is everyone signed up to the same federation? • Does it include the right mix of cross-national co- • operation? Does your favourite bit of software support federated IDs? Janet Moonshot The LAW Legal • Theory: anonymised data can be stored and • accessed without jumping through hoops. Practice: Risk of re-identification. Becomes easier the more data you have. • Medical records are hard to anonymise and still be useful. Ethical • Medical consent process adds more restrictions above data-protection law. • Limits data use & access even if anonymised. Controlled data access? • No ad-hoc analysis. • Access via restricted API only (“trusted intermediary model”). Policy development ongoing. • Cross juristiction for added fun. Summary We know where we want to get to. • No shortage of Vision There are lots of interesting tools and technologies out there. • Getting them to work coherently together will be a challenge. • Prototyping efforts are underway. • Need to leverage expertese and experience in other fields. Not simply technical issues: • Significant policy issues need to be worked out. • We have to bring the public along. Acknowledgements ISG: • James Beal • Helen Brimmer • Pete Clapham Global Alliance whitepaper: http://www.sanger.ac.uk/about/press/assets/130605-white-paper.pdf Million Cancer Genome Warehouse whitepaper http://www.eecs.berkeley.edu/Pubs/TechRpts/2012/EECS-2012-211.html